Study to assess pharmacokinetic, pharmacodynamic, safety and immunogenicity of a new adalimumab formulation in subjects with active rheumatoid arthritis. [Studie hodnotící farmakokinetiku, farmakodynamiku, bezpecnost a imunogenicitu noveho pripravku obsahujiciho adalimumab u subjektu s aktivni revmatoidni artritidou].
Phase of Trial: Phase II
Latest Information Update: 04 Aug 2017
At a glance
- Drugs Adalimumab (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors AbbVie
- 04 Aug 2017 This trial has been Discontinued in Belgium, according to European Clinical Trials Database.
- 10 Jun 2017 Biomarkers information updated
- 01 May 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History